title: Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma.
abstract: BACKGROUND
  despite the fact that the combination of gemcitabine (GCB) and docetaxel shows an increased benefit for disease-free survival and overall survival compared to GCB alone in patients with soft-tissue sarcoma, GCB mono-chemotherapy should be considered as a preferable option with respect to the combination because of its lower toxicity profile and the possibility of it being administered continuously for a long time period.
  
  
  METHODS
  we report a clinical case of a woman with advanced high-grade uterine leiomyosarcoma, refractory to ifosfamide, doxorubicin and trabectedin, who experienced a sustained and progressive response to GCB alone.
  
  
  CONCLUSIONS
  GCB given as mono-chemotherapy can obtain long-lasting tumour control in patients heavily pre-treated with various chemotherapeutic regimes for uterine LMS and should be considered as a possible option for this subset of patients.
authors.affiliation: Clinical Pharmacology and New Drugs Development Unit, Department of Medicine, European Institute of Oncology, Ripamonti 435, Milan, Italy. tommaso.de-pas@ieo.it
authors.forename: T
authors.initials: T
authors.lastname: De Pas
authors.forename: G
authors.initials: G
authors.lastname: Spitaleri
authors.forename: P D
authors.initials: PD
authors.lastname: Vigna
authors.forename: F
authors.initials: F
authors.lastname: Toffalorio
authors.forename: G
authors.initials: G
authors.lastname: Curigliano
authors.forename: A
authors.initials: A
authors.lastname: Gambino
authors.forename: S
authors.initials: S
authors.lastname: Boselli
authors.forename: C
authors.initials: C
authors.lastname: Catania
authors.forename: F
authors.initials: F
authors.lastname: de Braud